Expertise in
3
conditions

Hiroyuki Ogawa

Kobe, JP 
Expertise in
3
conditions
Kobe, JP 

Overview

Hiroyuki Ogawa practices practicing medicine in Kobe, Japan.

Mr. Ogawa is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Mediastinal Tumor, Lung Cancer, Lung Adenocarcinoma, Endoscopy, and Mastectomy.

He is actively involved in clinical research, co-authoring 83 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Kobe, 6500017, Japan
Other Locations
Nishinomiya-hama, Japan
Takatsuki, 5691125, Japan
Kashihara, Japan
Kashihara-shi, 6348522, Japan
Akashi, Japan
Nara-shi, Japan
Osaka, Japan
Kitaouji Cho, Japan
Shiki, Japan
Chuo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Enrollment Status: Terminated
Publish Date: April 29, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
View 4 Less Clinical Trials

83 Total Publications

Anatomical lung resection using the hinotori surgical robotic system: initial clinical experience with a standardized multiport approach.
Anatomical lung resection using the hinotori surgical robotic system: initial clinical experience with a standardized multiport approach.
Journal: General thoracic and cardiovascular surgery
Published: April 27, 2026

Frequently Asked Questions about Hiroyuki Ogawa

Is Hiroyuki Ogawa a top-rated expert for Mediastinal Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Hiroyuki Ogawa is classified as an Advanced expert for Mediastinal Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hiroyuki Ogawa participate in research or clinical trials?

Yes. Hiroyuki Ogawa has published 83 articles and abstracts on conditions like Mediastinal Tumor. You can view a list of Hiroyuki Ogawa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ogawa's expertise for a condition
ConditionClose
      View All 27 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile